60 Participants Needed

Nasogastric Tubes for Bronchiolitis

LC
Overseen ByLeroy Crawley, MS
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: Arkansas Children's Hospital Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 6 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This study aims to evaluate whether placing nasogastric tubes for gastric decompression improves respiratory distress for patients with bronchiolitis who are receiving oxygen via high-flow nasal cannula.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Nasogastric tube placement for bronchiolitis?

While there is no direct evidence for using nasogastric tubes specifically for bronchiolitis, nasogastric tubes are commonly used for feeding in children with feeding difficulties and have been shown to be an effective method for providing nutrition. They are also used in various medical settings to ensure patients receive necessary nutrients when they cannot eat by mouth.12345

Is it safe to use nasogastric tubes in humans?

Nasogastric tubes are generally safe for delivering nutrition and medication, but incorrect placement can lead to serious complications like pneumothorax (air in the chest cavity) or hemothorax (blood in the chest cavity). Proper training and verification of tube placement are crucial to avoid these risks.56789

How does nasogastric tube placement differ from other treatments for bronchiolitis?

Nasogastric tube placement is unique for bronchiolitis as it provides nutrition directly to the stomach when oral feeding is not possible, unlike other treatments that may focus on respiratory support. It is commonly used in children during the bronchiolitis season, especially in hospitals, to ensure they receive adequate nutrition while recovering.510111213

Research Team

DS

David Spiro, MD, MPH

Principal Investigator

AR Children's Hospital

Eligibility Criteria

This trial is for babies and toddlers up to 23 months old with bronchiolitis who are receiving oxygen through a high-flow nasal cannula. It's not suitable for those with tracheostomy, short gut syndrome, congenital heart disease, G-tube dependence, cranio-facial anomalies or bacterial pneumonia.

Inclusion Criteria

My doctor diagnosed me with bronchiolitis.
I am under 2 years old.
You are using a high-flow nasal cannula at a rate of 4 liters per minute or more.

Exclusion Criteria

You have had a condition called short gut syndrome in the past.
I was born with a heart condition.
I have had or currently have a tracheostomy.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive nasogastric tube placement for gastric decompression while on high-flow nasal cannula

60 minutes
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

1-2 days

Treatment Details

Interventions

  • Nasogastric tube placement
Trial Overview The study is testing if using nasogastric tubes to remove stomach contents can help ease breathing difficulties in young patients with bronchiolitis on high-flow oxygen therapy.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Nasogastric tube placementExperimental Treatment1 Intervention

Nasogastric tube placement is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:

πŸ‡ͺπŸ‡Ί
Approved in European Union as NG tube for:
  • Gastric decompression
  • Nutritional support
  • Medication administration
  • Removal of gastric contents
πŸ‡ΊπŸ‡Έ
Approved in United States as NG tube for:
  • Gastric decompression
  • Nutritional support
  • Medication administration
  • Removal of gastric contents
  • Bowel obstruction
  • Ileus
πŸ‡¨πŸ‡¦
Approved in Canada as NG tube for:
  • Gastric decompression
  • Nutritional support
  • Medication administration
  • Removal of gastric contents
πŸ‡―πŸ‡΅
Approved in Japan as NG tube for:
  • Gastric decompression
  • Nutritional support
  • Medication administration
πŸ‡¨πŸ‡³
Approved in China as NG tube for:
  • Gastric decompression
  • Nutritional support
πŸ‡¨πŸ‡­
Approved in Switzerland as NG tube for:
  • Gastric decompression
  • Nutritional support
  • Medication administration

Find a Clinic Near You

Who Is Running the Clinical Trial?

Arkansas Children's Hospital Research Institute

Lead Sponsor

Trials
141
Recruited
5,025,000+

Findings from Research

In a study of over 2.7 million hospital discharges, patients with nasogastric (NG) tubes or percutaneous endoscopic gastrostomy (PEG) had a significantly higher risk of bronchial aspiration and aspiration pneumonia, with odds ratios of 9.1 and 15.2 respectively, compared to those without these feeding devices.
Patients using NG tubes or PEG experienced longer hospital stays (averaging 9.2 and 12.7 more days) and higher diagnostic complexity and costs, indicating that while enteral nutrition is effective, it can lead to serious complications that impact overall healthcare resources.
Bronchopulmonary complications associated to enteral nutrition devices in patients admitted to internal medicine departments.Marco, J., Barba, R., LΓ‘zaro, M., et al.[2014]
In a study of 290 children with respiratory infections, the presence of indwelling nasogastric tubes (NGTs) did not significantly affect the rate of pulmonary aspiration, with rates of 29.8% in NGT patients compared to 32.3% in those without NGTs.
The results suggest that while pulmonary aspiration rates were high in children with underlying health issues, NGT feeding did not compromise the accuracy of salivagram tests used to assess aspiration risk.
Effect of nasogastric tube on salivagram result in paediatric patients.Wu, H., Zhao, X., Ting Kung, B., et al.[2020]
The Home Enteral Feeding Transitions (HEFT) program successfully increased the utilization of home enteral nutrition (HEN) for infants discharged from the NICU by 10%, indicating a more standardized approach to managing feeding dysfunction in neonates.
Parents reported high satisfaction with HEN (8.6/10), and the program demonstrated safety and effectiveness, with no increase in emergency department visits or admissions related to HEN after discharge.
Creation of a Standard Model for Tube Feeding at Neonatal Intensive Care Unit Discharge.White, BR., Ermarth, A., Thomas, D., et al.[2021]

References

Bronchopulmonary complications associated to enteral nutrition devices in patients admitted to internal medicine departments. [2014]
Effect of nasogastric tube on salivagram result in paediatric patients. [2020]
Creation of a Standard Model for Tube Feeding at Neonatal Intensive Care Unit Discharge. [2021]
Bedside enteral feeding tube placement into duodenum and jejunum. [2017]
Use of Nasogastric Feeding Tubes for Children at Home: A Template for Caregiver Education. [2018]
Evaluation of methods used to verify nasogastric feeding tube placement in hospitalized infants and children - A follow-up study. [2022]
Immediate chest radiograph interpretation by radiographers improves patient safety related to nasogastric feeding tube placement in children. [2022]
Nasogastric feeding practices: a survey using clinical scenarios. [2012]
Hemothorax Following Traumatic Dobhoff Tube Insertion. [2021]
Learning through leadership. [2019]
Inadvertent insertion of a nasogastric tube into both main bronchi of an awake patient: a case report. [2021]
The comparison of capnography and epigastric auscultation to assess the accuracy of nasogastric tube placement in intensive care unit patients. [2021]
13.United Statespubmed.ncbi.nlm.nih.gov
Malposition of feeding tubes in neonates: is it an issue? [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security